Safety and efficacy of cognitive training plus epigallocatechin-3-gallate in young adults with Down's syndrome (TESDAD): a double-blind, randomised, placebo-controlled, phase 2 trial

[1]  W. Rooney,et al.  Polyphenon E, non-futile at neuroprotection in multiple sclerosis but unpredictably hepatotoxic: Phase I single group and phase II randomized placebo-controlled studies , 2015, Journal of the Neurological Sciences.

[2]  J. Spencer,et al.  The mechanisms of action of flavonoids in the brain: Direct versus indirect effects , 2015, Neurochemistry International.

[3]  D. Valenti,et al.  Green tea EGCG plus fish oil omega-3 dietary supplements rescue mitochondrial dysfunctions and are safe in a Down's syndrome child. , 2015, Clinical nutrition.

[4]  S. Catuara-Solarz,et al.  A new cognitive evaluation battery for Down syndrome and its relevance for clinical trials , 2015, Front. Psychol..

[5]  J. Pujol,et al.  Anomalous brain functional connectivity contributing to poor adaptive behavior in Down syndrome , 2015, Cortex.

[6]  Sung-Joon Lee,et al.  The effect of bioactive compounds in tea on lipid metabolism and obesity through regulation of peroxisome proliferator-activated receptors , 2015, Current opinion in lipidology.

[7]  Assumpta Caixàs,et al.  Does motion-related brain functional connectivity reflect both artifacts and genuine neural activity? , 2014, NeuroImage.

[8]  Y. Hérault,et al.  Epigallocatechin-3-gallate, a DYRK1A inhibitor, rescues cognitive deficits in Down syndrome mouse models and in humans. , 2014, Molecular nutrition & food research.

[9]  O. Manzoni,et al.  Prefrontal Deficits in a Murine Model Overexpressing the Down Syndrome Candidate Gene Dyrk1a , 2014, The Journal of Neuroscience.

[10]  M. Dierssen,et al.  Environmental enrichment rescues DYRK1A activity and hippocampal adult neurogenesis in TgDyrk1A , 2013, Neurobiology of Disease.

[11]  Stefano Vicari,et al.  Executive functions in intellectual disabilities: a comparison between Williams syndrome and Down syndrome. , 2013, Research in developmental disabilities.

[12]  M. Dierssen.  Down syndrome: the brain in trisomic mode , 2012, Nature Reviews Neuroscience.

[13]  M. Haynes,et al.  Individual and environmental characteristics associated with cognitive development in Down syndrome: a longitudinal study. , 2012, Journal of applied research in intellectual disabilities : JARID.

[14]  E. Goldson,et al.  Antagonism of NMDA receptors as a potential treatment for Down syndrome: a pilot randomized controlled trial , 2012, Translational Psychiatry.

[15]  A. Tlili,et al.  Dyrk1a activates antioxidant NQO1 expression through an ERK1/2-Nrf2 dependent mechanism. , 2012, Molecular genetics and metabolism.

[16]  Á. Esteban,et al.  Cortical excitability in very mild Alzheimer’s disease: a long-term follow-up study , 2010, Journal of Neurology.

[17]  Á. Pascual-Leone,et al.  Transcranial Magnetic Stimulation Provides Means to Assess Cortical Plasticity and Excitability in Humans with Fragile X Syndrome and Autism Spectrum Disorder , 2010, Front. Syn. Neurosci..

[18]  Y. Hérault,et al.  DYRK1A, a Novel Determinant of the Methionine-Homocysteine Cycle in Different Mouse Models Overexpressing this Down-Syndrome-Associated Kinase , 2009, PloS one.

[19]  I. Kapetanovic,et al.  Exposure and toxicity of green tea polyphenols in fasted and non-fasted dogs. , 2009, Toxicology.

[20]  Desmond J. Smith,et al.  Green Tea Polyphenols Rescue of Brain Defects Induced by Overexpression of DYRK1A , 2009, PloS one.

[21]  A. Remppis,et al.  Green tea flavonoid epigallocatechin-3-gallate (EGCG) inhibits cardiac hERG potassium channels. , 2007, Biochemical and biophysical research communications.

[22]  Brenda Hanna-Pladdy,et al.  Dysexecutive Syndromes in Neurologic Disease , 2007, Journal of neurologic physical therapy : JNPT.

[23]  T. Tsai,et al.  Pharmacokinetics of (-)-epigallocatechin-3-gallate in conscious and freely moving rats and its brain regional distribution. , 2007, Journal of agricultural and food chemistry.

[24]  R. Nardone,et al.  Reduced short latency afferent inhibition in patients with Down syndrome and Alzheimer-type dementia , 2006, Clinical Neurophysiology.

[25]  W. Feng.  Metabolism of green tea catechins: an overview. , 2006, Current drug metabolism.

[26]  Alex Martin,et al.  Access the most recent version at doi: 10.1101/lm.251906 , 2006 .

[27]  P. Cohen,et al.  The specificities of protein kinase inhibitors: an update. , 2003, The Biochemical journal.

[28]  S. Morgan,et al.  A longitudinal study of children with Down syndrome who experienced early intervention programming. , 1993, Physical therapy.

[29]  W. Brown,et al.  Novel Epigenetic Regulation of Alpha-Synuclein Expression in Down Syndrome , 2014, Molecular Neurobiology.

[30]  M. Dierssen,et al.  Therapeutic approaches in the improvement of cognitive performance in Down syndrome: past, present, and future. , 2012, Progress in brain research.